Neumora Therapeutics closed at $0.57 on Nov 4, down 0.86%, 84.2% below its 52-week closing high. Volume of 2.8M shares was 1.28× its 20-day average (above normal).
Split-adjusted performance: +20.2% over one month, -75.7% over six months, -81.2% over one year.
Short interest was 5.6M shares at the Oct 15 settlement, down 15.7% from the prior report (6.9% of float, 2.3 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NMRANeumora Therapeutics | $0.5660 | −0.86% | −75.7% | — | — | — | $106.3M | |
| LENZLENZ Therapeutics | $3.46 | −1.14% | −64.3% | +9.7% | −581.8% | — | $108.7M | Compare |
| BDTXBlack Diamond Therapeutics | $1.90 | +4.97% | −32.6% | — | — | — | $109.2M | Compare |
| OTLKOutlook Therapeutics | $0.4621 | +0.46% | +99.4% | −99.4% | −233554.9% | — | $112.5M | Compare |
| VYGRVoyager Therapeutics | $1.87 | +2.19% | −55.2% | −39.1% | −773.2% | — | $115.2M | Compare |
| ENGNenGene Therapeutics | $1.72 | +6.17% | −80.6% | — | — | — | $115.3M | Compare |
| ARMPArmata Pharmaceuticals | $3.14 | +1.62% | −65.3% | +15.7% | 2953.8% | — | $116.8M | Compare |
| AVXLAnavex Life Sciences | $1.26 | +5.00% | −62.3% | — | — | — | $116.8M | Compare |
| HUMAHumacyte | $0.4500 | +2.16% | −54.2% | +34.9% | −9064.5% | — | $125.0M | Compare |
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
